{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Bilateral tubal occlusion/ligation.', 'Bilateral tubal occlusion via hysteroscopy (i.e., Essure), provided', 'a', 'hysterosalpingogram confirms success of the procedure.', 'Vasectomized partner(s), provided the vasectomized partner has received', 'medical assessment of the surgical success and is the sole sexual partner of the', 'WOCBP trial participant.', 'Intrauterine device (IUD).', 'Intrauterine hormone-releasing system (IUS).', 'True abstinence: Refraining from heterosexual intercourse when this is in line', 'with the preferred and usual lifestyle of the subject (periodic abstinence', '[e.g., calendar, ovulation, symptothermal, post-ovulation methods] and', 'withdrawal are not acceptable).', 'If required per local practices, male or female condom with or without spermicide OR', 'cap, diaphragm or sponge with spermicide should be used in addition to one of the birth', 'control methods listed above (excluding true abstinence).', 'Male subjects who are sexually active with a WOCBP, even if the male subject has', 'undergone successful vasectomy, must agree from randomization through at least', '6 months after the last dose of blinded investigational product to use condoms and his', 'female partner(s) must use at least one of the contraceptive measures (as defined in the', 'protocol for female study subjects of childbearing potential).', 'Male subject agrees not to donate sperm from randomization through at least 6 months', 'after the last dose of blinded investigational product.', '5.3', 'Efficacy, Pharmacokinetic, Biomarker, Pharmacogenetic', 'and Safety Assessments/Variables', '5.3.1', 'Efficacy and Safety Measurements Assessed and Flow', 'Chart', 'Study procedures described are listed in the following section of this protocol and are', 'summarized in tabular format in Appendix C, Study Activities.', '42']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.1.1', 'Study Procedures', 'Unless otherwise stated, the baseline measurement for any given variable will be defined', 'as the last value obtained for the variable prior to the first dose of blinded investigational', 'product.', 'Screening procedures must be performed within 21 days prior to randomization, with the', 'exception of radiographic assessments (CT scan or MRI including the head, chest, and', 'abdomen) which may be performed within 28 days prior to randomization. The collection', 'of tumor material for DLL3 testing will be provided any time after the signing of the', 'informed consent and prior to randomization. Randomization may occur within 3 days', 'prior to C1D1.', 'Subsequent study procedures should be performed within 3 days prior to the scheduled', 'treatment visits, within a 3 day window during the non-treatment visits, and within a', '1 week window during the post-treatment follow up, and survival follow up phase unless', 'otherwise indicated.', 'The results of all screening and evaluations at the time of randomization must be within', 'clinically acceptable limits, upon review by the investigator, before a subject can be', 'randomized. Subjects will not be randomized in the study if laboratory or other screening', 'results are unacceptable. Subjects are allowed to rescreen and have laboratory samples', 'redrawn to meet eligibility within the same 21 day screening window. Subjects who meet', 'the inclusion criteria and do not meet any of the exclusion criteria may be randomized.', 'Informed Consent', 'Signed informed consent will be obtained from the subject before any study-specific', 'procedures are undertaken or before any prohibited medications are withheld from the', 'subject in order to participate in this study. Informed consent may be obtained before the', '21-day screening window. For the optional tumor biopsy procedure at time of disease', 'progression an optional tumor material biopsy procedure informed consent should be', '43']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'completed. Details about how informed consent will be obtained and documented are', 'provided in Section 9.3.', 'Subjects will be considered screen failures if the informed consent has been signed and a', 'study-specific procedure has been performed (e.g., central laboratories drawn), but subject', 'does not randomize into the study. The reason for screen failure will be documented in', 'the source and will be captured in the eCRF.', 'Tumor Material at Screening', 'For all subjects, archived or fresh tumor material must be submitted to the AbbVie', 'designated central IHC laboratory for determination of DLL3 expression prior to', 'randomization, as per Appendix C, Study Activities.', 'Tumor material testing for DLL3 status may occur at any time after initial diagnosis for', 'subjects who provide consent. These subjects must be registered in IRT. Eligibility will', 'depend on the fulfillment of all other inclusion and exclusion criteria and the trial status', '(whether the study is still open for accrual).', 'For purposes of the study, \"unknown\" status is possible if all available samples were', 'tested and failed due to unforeseen technical or logistical reasons; subject with no tumor', \"sample will not be eligible for the trial or subject with sample not fulfilling sponsor's\", 'specifications (different method of tissue fixation, known necrotic, too few cells etc.) will', 'not be eligible.', 'Medical and Surgical History (Including Malignancy History); Adverse Event and', 'Prior/Concomitant Medication Assessment', 'The following will be collected during the Screening Visit:', 'Medical history, including demographics and documentation of any clinically', 'significant medical condition and/or surgical history', 'History of tobacco and alcohol use:', '44']\n\n###\n\n", "completion": "END"}